Resatorvid (or TAK-242) was first discovered in 2006, as a suppressor of cytokine production and inhibitor of TLR4 intracellular signaling, while developing novel drugs to treat and/or prevent the septic shock associated with infections caused by Gram-negative bacteria [16, 17]. Here, TLR4 is linked to infection.